Skip to main content
. 2018 May 7;8:129. doi: 10.3389/fcimb.2018.00129

Table 6.

Demographics, clinical data and laboratory perameter at admission in survivors and non-survivors of patients with HFRS.

Variables Survivors (n = 133) Non-survivors (n = 13) P-value
Male, n (%) 100 (75.2) 9 (69.2) 0.891
Age, years 43.92 ± 16.18 55.76 ± 10.28 0.010
Max temperature, °C 38.99 ± 0.75 38.91 ± 0.77 0.723
Admitted days after fever 5.99 ± 3.59 6.46 ± 3.07 0.645
SBP, mmHg 121.17 ± 17.94 114.69 ± 22.50 0.226
DBP, mmHg 78.81 ± 13.09 69.85 ± 22.36 0.030
Smoking, n (%) 63 (47.4) 8 (61.5) 0.329
Alcohol consumption, n (%) 59 (44.4) 7 (53.8) 0.512
COMORBIDITY
Hypertension, n (%) 20 (15) 3 (23.1) 0.718
Diabetes mellitusm, n (%) 5 (3.8) 2 (15.4) 0.119
Coronary heart disease, n (%) 4 (3) 1 (7.7) 0.377
HFRS-RELATED COMPLICATION
Hemorrhage, n (%) 71 (53.4) 12 (92.3) 0.007
Bacterial infection, n (%) 76 (57.1) 11 (84.6) 0.054
Hepatic injury, n (%) 68 (51.1) 10 (76.9) 0.075
Sepsis, n (%) 2 (1.5) 4 (30.8) 0.001
MODS, n (%) 2 (1.5) 6 (46.2) <0.001
Arrhythmia, n (%) 9 (6.8) 0 1.000
Blood transfusion, n (%) 44 (33.1) 11 (84.6) 0.001
CRRT, n (%) 28 (21.1) 11 (84.6) <0.001
Hospital stay, days 13.28 ± 7.11 9.08 ± 6.47 0.042
LABORATORYPARAMETERS
WBC, × 109 cells/L 11.78 ± 7.66 13.66 ± 6.79 0.395
PLT, × 109 cells/L 86.23 ± 79.07 54.92 ± 44.68 0.163
Neutrophils percentage, (%) 66.38 ± 15.20 77.34 ± 10.16 0.012
Lymphocytes percentage, (%) 1.72 (2.86) 1.69 (1.34) 0.031
PCT, (ng/ml) 1.22 (0.03-62.91) 7.65 (1.06–58.53) <0.001
Lg PCT 0.10 ± 0.68 0.87 ± 0.48 <0.001

SBP, systolic blood pressure; DBP, diastolic blood pressure; MODS, multiple organ dysfunction syndrome; CRRT, continuous renal replacement therapy; WBC, white blood cell count; PLT, platelet; Lg PCT, procalcitonin after log10 transformation.